Business

InspireMD to Report First Quarter 2022 Financial Results on May 10, 2022 and Provide Corporate Business Update

Earnings Conference Call to be held Tuesday, May 10, 2022, at 8:30 a.m. ET TEL AVIV, Israel, April 28, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq:

articleInspiremd Inc.April 28, 20223/company/inspiremd-inc/news/inspiremd-to-report-first-quarter-2022-financial-results-on-may-10-2022-and-provide-corporate-business-update
InspireMD to Report First Quarter 2022 Financial Results on May 10, 2022 and Provide Corporate Business Update

About this update from Inspiremd Inc.

[{"type":"text","content":"Earnings Conference Call to be held Tuesday, May 10, 2022, at 8:30 a.m. ET\nTEL AVIV, Israel, April 28, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report first quarter 2022 financial results on Tuesday, May 10, 2022, before the market opens. Management will host a conference call and webcast with the investment community at 8:30 am (ET) that same day to review financial results and provide an update on corporate developments. Title:InspireMD First Quarter 2022 Financial Results and Corporate Update Conference Call and Webcast Date:Tuesday, May 10, 2022 Time:8:30 a.m. ET Conference Call Details:Toll-Free: 877-407-4018International: 201-689-8471Conference ID: 13729033 The conference call will be webcast live from the Company’s website and will be available via the following links: Webcast:Webcast Link - Click Herehttps://www.inspiremd.com/en/investors/investor-relations/ The webcast should be accessed 15 minutes prior to the conference call start time. A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the Company’s website. About InspireMD, Inc. InspireMD seeks to utilize its proprietary MicroNet® technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free, long-term outcomes. Forward-looking Statements This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential”, “scheduled” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. For example, the company is using forward looking statements when it discusses the expansion of its portfolio and potential indications and that the CGuard Carotid stent provid...

More updates from Inspiremd Inc.